On October 1, 2021, Pharmaceutical Company “Merck and Ridgeback Biotherapeutics” announced the early results of Phase-3 trials of its anti-viral drug called molnupiravir. As per the results, Molnupiravir has reduced the chances of hospitalisation by half among COVID-19 patients with mild or moderate symptoms.
Molnupiravir: New drug to treat COVID-19
Placebo trials comprised of testing a drug on thousands of people. Among them, some get the drug and some do not.In the group that do not get placebo, 53 patients or 14% of the patients were either hospitalised or had died. On the other hand, among the group that got drug, 28 patients or 7.3% were hospitalised or succumbed to the covid-19 infection.
Patients were monitored for 29 days. No deaths were reported among the patients who received molnupiravir. On the other hand, eight deaths were reported among those received placebo.
